Skip to content
All Podcasts – Lifestyle
Author:
Eton Pharmaceuticals
Boehringer Ingelheim’s oncology portfolio shows strong promise across multiple cancers at ASCO 2026
May 22, 2026
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)
May 20, 2026
Eton Pharmaceuticals Reports First Quarter 2026 Financial Results
May 14, 2026
Eton Pharmaceuticals to Participate in Upcoming Investor Conferences
May 12, 2026
Eton Pharmaceuticals to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
May 4, 2026
Eton Pharmaceuticals relaunches HEMANGEOL® (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution
May 1, 2026
Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700
April 27, 2026
Beamion LUNG-1 study results for zongertinib in treatment-naïve patients with HER2-mutant advanced NSCLC published in The New England of Journal of Medicine
April 17, 2026
/C O R R E C T I O N — Boehringer Ingelheim/
April 16, 2026
Eton Pharmaceuticals Announces CFO Succession Plan
April 16, 2026
1
2
Next Page
→